tetano
Editor, Senior Moderator
Appl Microbiol Biotechnol. 2012 Jul 21. [Epub ahead of print]
CAP, a new human suspension cell line for influenza virus production.
Genzel Y, Behrendt I, R?dig J, Rapp E, Kueppers C, Kochanek S, Schiedner G, Reichl U.
Source
Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany, genzel@mpi-magdeburg.mpg.de.
Abstract
Forced by major drawbacks of egg-based influenza virus production, several studies focused on the establishment and optimization of cell-based production systems. Among numerous possible host cell lines from duck, monkey, canine, chicken, mouse, and human origin, only a few will meet regulatory requirements, accomplish industrial standards, and result in high virus titers. From primary virus isolation up to large-scale manufacturing of human vaccines, however, the most logical choice seems to be the use of human cell lines. For this reason, we evaluated the recently established CAP cell line derived from human amniocytes for its potential in influenza virus production in suspension culture in small scale shaker flask and stirred tank bioreactor experiments. Different human and animal influenza viruses could be adapted to produce hemagglutination (HA) titers of at least 2.0 log(10) HA units/100 μL without further process optimization. Adjusting trypsin activity as well as infection conditions (multiplicity of infection, infection medium) resulted in HA titers of up to 3.2 log(10) HA units/100 μL and maximum cell-specific virus productivities of 6,400 virions/cell (for human influenza A/PR/8/34 as a reference). Surface membrane expression of sialyloligosaccharides as well as HA N-glycosylation patterns were characterized. Overall, experimental results clearly demonstrate the potential of CAP cells for achieving high virus yields for different influenza strains and the option to introduce a highly attractive fully characterized human cell line compliant with regulatory and industrial requirements as an alternative for influenza virus vaccine production.
PMID:
22821436
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22821436
CAP, a new human suspension cell line for influenza virus production.
Genzel Y, Behrendt I, R?dig J, Rapp E, Kueppers C, Kochanek S, Schiedner G, Reichl U.
Source
Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Sandtorstr. 1, 39106, Magdeburg, Germany, genzel@mpi-magdeburg.mpg.de.
Abstract
Forced by major drawbacks of egg-based influenza virus production, several studies focused on the establishment and optimization of cell-based production systems. Among numerous possible host cell lines from duck, monkey, canine, chicken, mouse, and human origin, only a few will meet regulatory requirements, accomplish industrial standards, and result in high virus titers. From primary virus isolation up to large-scale manufacturing of human vaccines, however, the most logical choice seems to be the use of human cell lines. For this reason, we evaluated the recently established CAP cell line derived from human amniocytes for its potential in influenza virus production in suspension culture in small scale shaker flask and stirred tank bioreactor experiments. Different human and animal influenza viruses could be adapted to produce hemagglutination (HA) titers of at least 2.0 log(10) HA units/100 μL without further process optimization. Adjusting trypsin activity as well as infection conditions (multiplicity of infection, infection medium) resulted in HA titers of up to 3.2 log(10) HA units/100 μL and maximum cell-specific virus productivities of 6,400 virions/cell (for human influenza A/PR/8/34 as a reference). Surface membrane expression of sialyloligosaccharides as well as HA N-glycosylation patterns were characterized. Overall, experimental results clearly demonstrate the potential of CAP cells for achieving high virus yields for different influenza strains and the option to introduce a highly attractive fully characterized human cell line compliant with regulatory and industrial requirements as an alternative for influenza virus vaccine production.
PMID:
22821436
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22821436